DALLAS / Apr 03, 2023 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) will release its first quarter 2023 results before the market opens on Tuesday, April 25, 2023, to be followed by a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time).
A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates or has ownership interests in more than 465 ambulatory surgery centers and surgical hospitals. We also operate 61 acute care and specialty hospitals, approximately 110 other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Last Trade: | US$128.82 |
Daily Change: | -0.89 -0.69 |
Daily Volume: | 16,288 |
Market Cap: | US$12.250B |
October 29, 2024 July 24, 2024 April 30, 2024 February 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB